This is the largest double-blind randomized controlled trial designed to determine the utility of tylenol and diphenhydramine in reducing the incidence of allergic or febrile non-hemolytic transfusion reactions (abstract). Included patients were those admitted to a leukemia or BMT unit with no prior transfusion reaction, and all transfusions were leukoreduced. They found the incidence of reactions was 1.5/100 transfusions in the placebo group and 1.4/100 transfusions in the intervention group. Based on this (and other smaller and older trials), there is no benefit to pre-meds in cancer patients receiving leukoreduced transfusion products. As an editorialist states, it would be nice to see corroboration in a more general medical population, but for now, routine pre-med use should be discouraged (editorial)
|
November 12, 2008 |
0 
Share This Post
About the Author: Danielle Scheurer
Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.
Categories
Related Posts
July 2, 2015 |
0I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
September 8, 2014 |
3 As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
July 6, 2013 |
0This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment